Brinson Patrick Initiates StemCells (STEM) With Outperform Rating, PT Set $7

StemCells (STEM) shares climbed in Wednesday’s pre-market session, after analysts at Brinson Patrick initiated coverage of the stem-cell therapeutics research-and-development company with an investment rating at outperform and a price target of $7 per share.

The price target implies expectations for the stock to more than triple from its Tuesday closing price of $2. The shares were up 7% at $2.14 in recent pre-market trading, in a 52-week range of $1.15 to $2.34.

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies.


Joseph Clements, CPA, is a senior analyst for The Downtown Leader. If you have a great story idea for Joseph Clements, you can write at [ ].